Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Q1 2020 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

May 06, 2020 / 09:00PM GMT
Release Date Price: $66.26 (+2.44%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Ultragenyx First Quarter 2020 Financial Results Conference Call. (Operator Instructions)

Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the call over to your speaker today, Ms. Danielle Keatley. Please go ahead.

Danielle Keatley
Ultragenyx Pharmaceutical Inc. - Senior Director of IR & Corporate Communications

Good afternoon, and welcome to the Ultragenyx Pharmaceutical Financial Results and Corporate Update Conference Call for the first quarter 2020. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.

I am Danielle Keatley, Senior Director of Investor Relations. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Shalini Sharp, Chief Financial Officer; Camille Bedrosian, Chief Medical Officer; and Erik Harris, Chief Commercial Officer.

I would like to remind investors that this call will include forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot